Integrated ADC & Complex Biologics Discovery
From antibody engineering to preclinical candidate — our integrated services combine antibody discovery, protein engineering, linker-payload design, and conjugation to accelerate end-to-end ADC development.
- Integrated Services
Target Preclinical Candidate
Antibody × Linker-Payload × Conjugation × Translational Biology — one integrated services model across the full discovery continuum
Evaluation
Engineering
Candidate
Phase 1
Antibody Discovery & Engineering
- Hybridoma and single B-cell discovery
- VHH, phage, and yeast display libraries
- Humanized & common light-chain mouse
- Epitope mapping & affinity optimization
- Bispecific and protein engineering
- Internalization activity screening
- PiggyBac-enabled kill assays
Phase 2
Linker-Payload & Conjugation
- Payload selection — Topo1, MMAE/F, novel cytotoxics
- Linker design — cleavable vs non-cleavable
- Dual linker strategies
- Site-specific conjugation — mTG, engineered cysteine
- DAR optimization & hydrophobicity control
- Synergy profiling across payload combinations
Phase 3
ADC Functional Characterization
- Cytotoxicity — sensitive & resistant cell lines
- Bystander killing in heterogeneous tumor models
- Internalization & intracellular trafficking
- Serum stability & controlled payload release profiling
- Bioanalytics & multi-platform bioassays
Phase 4
In Vivo Pharmacology Services
- CDX / PDX efficacy studies in xenograft models
- Integrated PK/PD & exposure-response modeling
- Comprehensive PK profiling for candidate selection
- Early safety, tolerability & dose range finding
- Pharmacodynamic biomarker development
- Outcomes
What This Enables
Our integrated services are built to reduce time, cost, and risk at every stage — delivering stronger candidates and smarter decisions from first design to preclinical readiness.
-
Faster Optimization Cycles
Rapid turnaround to move programs from concept to candidate in weeks, not months. -
Parallel Linker-Payload Evaluation
Explore more combinations, faster and smarter, with head-to-head comparative data. -
Reduced Clinical Failure Risk
Better design, better selection, better outcomes — with data-driven decision-making at every step.
- Developability
Early Developability
Comprehensive analytical and developability assessment to de-risk candidates early and build a strong foundation for IND-enabling studies
Optimized ADC candidate ready for IND-enabling studies — high-potential ADCs advanced with confidence and speed
Analytical Characterization
DAR, aggregates, free payload, and impurity profiling
Stability & Forced Degradation
Chemical, physical, and formulation stability assessment
IND Strategy & CMC Planning
Aligned with regulatory expectations to accelerate clinical entry
Scalable & Transfer-Ready
Process and analytics optimized for seamless technology transfer to GMP
follow up within 1–2 business days with a tailored proposal.
- Antibody discovery & protein engineering
- Linker-payload design & bioconjugation
- Characterization & in vivo pharmacology
- Full continuum from concept to preclinical candidate
Start Your Program with Xcellon
Tell us about your program and our team of ADC experts will
follow up within 1–2 business days with a tailored proposal.
- Antibody discovery & protein engineering
- Linker-payload design & bioconjugation
- Characterization & in vivo pharmacology
- Full continuum from concept to preclinical candidate
